Star Combo Pharma Limited (S66) Fair Value & Analysis
Consumer Defensive · AU · Market cap A$20.9M
Fair value as of: Jun 26, 2026
Analysis
Star Combo Pharma Limited (S66) currently trades at A$0.1350, while our model-based Fair Value estimate is A$0.3600 — implying the stock looks roughly 166.7% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products. It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its products under the Costar, Living Healthy, Amax, and J&K brands. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Star Combo Pharma Limited (S66) undervalued?
What is the fair value of S66?
What is the quality score of S66?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.